CVD Clinical Trial
— APORIASOfficial title:
Phase 4 of Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
Verified date | September 2015 |
Source | Jinling Hospital, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ministry of Health |
Study type | Interventional |
Severe intracranial atherosclerosis with concomitant stenosis is responsible for approximately 10% of all strokes. Retrospective studies have indicated that up to 50% of patients with a recently symptomatic intracranial stenosis experience recurrent ischemic events. Due to the high stroke risk, patients with high grade 70% symptomatic intracranial stenosis represent the main target group for endovascular treatment. Atorvastatin is widely used in the treatment of hyperlipidemia, especially after acute myocardial infarction. High-dose atorvastatin has been known to stop the progression of atherosclerosis and to decrease the levels of inflammatory markers. Several recent clinical trials have proved atorvastatin can reduce restenosis after stent implantation in coronary artery. But the feasibility of atorvastatin in preventing restenosis in patients with intracranial stenting has not been evaluated.The purpose of this prospective, randomized, single-blinded trial is to evaluate the effect of atorvastatin 80 mg daily in preventing restenosis and related vascular events in patients with intracranial stent implantation.
Status | Completed |
Enrollment | 100 |
Est. completion date | July 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 1: Clinical inclusion criteria 1. Subject is =18 years old 2. Eligible for percutaneous endovascular intervention 3. Documented severe (70%) symptomatic intracranial stenosis 4. Acceptable candidate for intracranial stenting 5. Subject (or legal guardian) understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed 6. Subject willing to comply with all specified follow-up evaluations - 2: Angiographic Inclusion Criteria 1. Target lesion located in intracranial internal artery, intracranial vertebral artery, basilar artery or middle cerebral artery 2. Target lesion must be symptomatic 3. Target lesion diameter stenosis =70% 4. Reference vessel diameter (RVD): =2.0 mm to =6.0 mm 5. Cumulative target lesion length (area to be treated must be completely coverable by one study stent) =30 mm 6. Target lesion is presumed accessible by endovascular treatment. 7. One non target lesion may be treated in a non target vessel 8. Non-target lesion in non-target vessel must be treated with a commercially available stent. 9. Treatment of a non target lesion (if performed) must be deemed a clinical angiographic success, without requiring use of unplanned additional stent(s). 10. Treatment must be completed prior to treatment of target lesion Exclusion Criteria: - Contraindication to ASA, or to both clopidogrel and ticlopidine - Known hypersensitivity to atorvastatin - Known allergy to stainless steel - Known allergy to platinum - Previous treatment of the target vessel with angioplasty - Previous treatment of the target vessel with stent - Previous treatment of any non target vessel with stent within 9 months of the index procedure - Planned endovascular treatment to post index procedure - Planned or actual target vessel treatment with an unapproved device, directional or rotational intracranial atherectomy, laser, cutting balloon or transluminal extraction catheter immediately prior to stent placement - Cerebral infarction within 1 month prior to the index procedure - Myocardial infarction within the past 1 month - Uncontrollable malignant hypertension (>180/110 mmHg) before procedure - Acute or chronic renal dysfunction (creatinine > 2.0 mg/dl or 177 µmol/l) - Anticipated treatment with atorvastatin or other statins during the 12 months after the index procedure - Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure - Leukopenia (leukocyte count < 3.5 × 109/liter) - Thrombocytopenia (platelet count < 100,000/mm3) - Thrombocytosis (> 750,000/mm3) - Seizure 12 months before procedure - Intracranial tumor - Active peptic ulcer or active gastrointestinal (GI) bleeding - Male or female with known intention to procreate within 12 months after the index procedure - Positive pregnancy test within 7 days before the index procedure, or lactating - Life expectancy of less than 24 months due to other medical conditions - Co-morbid condition(s) that could limit the subject's ability to comply with study follow-up requirements or impact the scientific integrity of the study - Currently participating in another investigational drug or device study - Current treatment, or past treatment within 6 months with atorvastatin or other statins |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Department of Neurology, Jinling Hospital, Nanjing University School of Medicine | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jinling Hospital, China |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Target lesion failure | Target lesion failure (TLF) will be conducted in-hospital and planned at 30 days, 3 months, 6 months, and 12 months. In-stent late diameter loss and stent patency will be evaluated by DSA (digital subtraction angiography) 12 months after the index procedure. | at two year | Yes |
Secondary | Clinical endpoint | Clinical endpoint measurements, TIA, minor stroke, ipsilateral stroke, major stroke, myocardial infarction, cardiovascular death and death, will be conducted in-hospital and planned at 30 days, 3 months, 6 months, and 12 months. | at two years | Yes |
Secondary | Angiographic follow-up | Angiographic follow-up is planned at 3 and 9 months after the index procedure with TCD or CTA for evaluating in-stent blood flow velocity and stent patency. | at two years | Yes |
Secondary | In-segment binary restenosis rate 12 months after the index procedure | In-segment binary restenosis rate 12 months after the index procedure will be evaluated with DSA. | at two years | Yes |
Secondary | Effects of atorvastatin on blood lipid and inflammatory levels | Effects of atorvastatin on blood lipid and inflammatory levels will be evaluated by testing serum CRP, LDL, HDL and MMP-9 at baseline and at 12 month after the index procedure. | at two years | Yes |
Secondary | Effects of atorvastatin treatment on neurological function outcomes | Effects of atorvastatin treatment on neurological function outcomes will be evaluated by mRS,NIHSS,MMSE (modified Rankin Scale,an scale used to assess levels of neurological impairment; The National Institute of Health stroke scale, a standardized method used by physicians and other health care professionals to measure the level of impairment caused by a stroke; mini-mental state examination, a brief 30-point questionnaire test that is used to screen for cognitive impairment) tested 1, 3, 6, 9 and 12 months after the index procedure. | at two years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02480504 -
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
Active, not recruiting |
NCT00038727 -
Diabetes Prevention Program Outcomes Study
|
Phase 3 | |
Completed |
NCT03967678 -
Omega (n)-3 PUFA Enriched Beef & Health Outcomes.
|
N/A | |
Completed |
NCT01251302 -
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
|
||
Not yet recruiting |
NCT05716659 -
EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
|
||
Withdrawn |
NCT02158754 -
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
|
||
Completed |
NCT01077388 -
e-Care for Heart Wellness
|
Phase 3 | |
Completed |
NCT04384029 -
The Geneva Covid-19 CVD Study
|
||
Active, not recruiting |
NCT02382822 -
Copenhagen Co-morbidity in HIV Infection Study
|
||
Active, not recruiting |
NCT01825668 -
Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy
|
N/A | |
Completed |
NCT02223286 -
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
|
N/A | |
Completed |
NCT00289237 -
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
|
N/A | |
Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
Completed |
NCT03636529 -
Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes
|
N/A | |
Completed |
NCT00500617 -
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
|
||
Completed |
NCT00500708 -
Diagnostic Investigation of Sudden Cardiac Event Risk
|
N/A | |
Completed |
NCT00583297 -
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
|
N/A | |
Completed |
NCT02405754 -
Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.
|